oncolog-hematolog
ro
hematologie
Bibliografie
complications may lead to a “causal” antioxidant therapy. lation. Int J Biochem Cell Biol 2005; 37:927-934.
Diabetes Care 2003; 26: 1589-1596.
31. Elfering S.L., Haynes V.L., Traaseth N.J., Ettl A., Giulivi C.
17. Kang Y., Edwards L.G., Thornalley P.J. Effect of methylg-
Aspects, mechanism, and biological relevance of mitochon-
lyoxal on human leukaemia 60 cell growth: modification of
drial protein nitration sustained by mitochondrial nitric
DNA G1 growth arrest and induction of apoptosis. Leuk Res
oxide synthase. Am J Physiol 2004; 286:H22-H29.
1996; 20:397-405.
18. Beisswenger P.J., Howell S.K., Nelson R.G., Mauer M., Sz-
32. Ceriello A., Hanefeld M., Leiter L., Monnier L., Moses A.,
wergold B.S. Alpha-oxoaldehyde metabolism and diabetic
Owens D., Tajima N., Tuomilehto J. Postprandial glucose
complications. Biochem Soc Trans 2003; 31:1358-1363.
regulation and diabetic complications. Arch Intern Med
19. Lo T.W., Westwood M.E., McLellan A.C., Selwood T., Thor- 2004; 164:2090-2095.
nalley P.J. Binding and modification of proteins by meth-
33. Ceriello A. Postprandial hyperglycemia and diabetes com-
ylglyoxal under physiological conditions. A kinetic and
plications: is it time to treat? Diabetes 2005; 54: 1-7.
mechanistic study with N alpha-acetylarginine, N alpha-
34. Rohlfing C.L., Wiedmeyer H.M., Little R.R., England J.D.,
acetylcysteine, and N alpha-acetyllysine, and bovine serum
Tennill A., Goldstein D.E. Defining the relationship between
albumin. J Biol Chem 1994; 269:32299-32305.
20. Papoulis A., al-Abed Y., Bucala R. Identification of N2-(1-
plasma glucose and HbA1c: analysis of glucose profiles and
carboxyethyl)guanine (CEG) as a guanine advanced glyco-
HbA1c in the Diabetes Control and Complications Trial.
sylation end product. Biochemistry 1995; 34: 648-655.
Diabetes Care 2002; 25:275-278.
21. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Aga- 35. Monnier L., Lapinski H., Colette C. Contributions of fast-
lou S., Babaei-Jadidi R., Dawnay A. Quantitative screening ing and postprandial plasma glucose increments to the
of advanced glycation endproducts in cellular and extra-
overall diurnal hyperglycemia of type 2 diabetic patients.
cellular proteins by tandem mass spectrometry. Biochem J
Diabetes Care 2003; 26:881-885.
2003; 375: 581-592.
36. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R.,
22. Rosca M.G., Monnier V.M., Szweda L.I., Weiss M.F. Altera-
tions in renal mitochondrial respiration in response to the
Maier A., Esposito K., Giugliano D. Effect of postprandial
reactive oxoaldehyde methylglyoxal. Am J Physiol 2002;
hypertriglyceridemia and hyperglycemia on circulating ad-
283: F52-F59.
hesion molecules and oxidative stress generation and the
23. Rosca M.G., Mustata T.G., Kinter M.T., Ozdemir A.M., possible role of simvastatin treatment. Diabetes 2004; 53:
Kern T.S., Szweda L.I., Brownlee M., Monnier V.M., Weiss 701-710.
M.F. Glycation of mitochondrial proteins from diabetic rat
37. Ahmed N., Babaei-Jadidi R., Howell S.K., Thornalley P.J.,
kidney is associated with excess superoxide formation. Am
Beisswenger P.J. Glycated and oxidized protein degradation
J Physiol 2005; 289: F420-F430.
products are indicators of fasting and postprandial hyper-
24. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J.,
Dahms W., Cleary P.A., Lachin J., Genuth S. Skin collagen
glycemia in diabetes. Diabetes Care 2005; 28: 2465-2471.
glycation, glycoxidation, and crosslinking are lower in sub-
38. Schiekofer S., Andrassy M., Chen J., Rudofsky G., Schneider
jects with long-term intensive versus conventional therapy
J., Wendt T., Stefan N., Humpert P., Fritsche A., Stumvoll M.,
of type 1 diabetes: relevance of glycated collagen products Schleicher E., Haring H.U., Nawroth P.P., Bierhaus A. Acute
versus HbA1c as markers of diabetic complications. DCCT hyperglycemia causes intracellular formation of CML and
Skin Collagen Ancillary Study Group. Diabetes Control and
activation of ras, p42/44 MAPK, and nuclear factor kappaB
Complications Trial. Diabetes 1999; 48: 870-880.
in PBMCs. Diabetes 2003; 52:621-633.
25. Genuth S., Sun W., Cleary P., Sell D.R., Dahms W., Malone
39. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N.,
J., Sivitz W., Monnier V.M. DCCT Skin Collagen Ancillary
Nadler J.L. Evidence that pioglitazone, metformin and pent-
Study Group. Glycation and carboxymethyllysine levels in
skin collagen predict the risk of future 10-year progression
oxifylline are inhibitors of glycation. Clin.Chim.Acta 2000;
of diabetic retinopathy and nephropathy in the diabetes
301:65-77.
control and complications trial and epidemiology of diabe- 40. Miyata T., van Ypersele D.S., Ueda Y., Ichimori K., Inagi
tes interventions and complications participants with type R., Onogi H., Ishikawa N., Nangaku M., Kurokawa K. Angio-
1 diabetes. Diabetes 2005; 54: 3103-3111.
tensin II receptor antagonists and angiotensinconverting
26. Kilhovd B.K., Juutilainen A., Lehto S., Ronnemaa T., Torje-
enzyme inhibitors lower in vitro the formation of advanced
sen P.A., Birkeland K.I., Berg T.J., Hanssen K.F., Laakso M.
glycation end products: biochemical mechanisms. J Am Soc
High serum levels of advanced glycation end products
Nephrol 2002; 13:2478-2487.
predict increased coronary heart disease mortality in non-
diabetic women but not in nondiabetic men: a population-
41. Ceriello A., Assaloni R., Da Ros R., Maier A., Piconi L.,
based 18-year follow-up study. Arterioscler Thromb Vasc
Quagliaro L., Esposito K., Giugliano D. Effect of atorvas-
Biol 2005; 25: 815-820.
tatin and irbesartan, alone and in combination, on post-
27. Wu X., Monnier V.M. Enzymatic deglycation of proteins. prandial endothelial dysfunction, oxidative stress, and in-
Arch Biochem Biophys 2003; 419: 16-24.
flammation in type 2 diabetic patients. Circulation 2005;
28. Zorov D.B., Juhaszova M., Sollott S.J. Mitochondrial ROS-
111: 2518-2524.
induced ROS release: an update and review. Biochim Bio-
42. Lapolla A., Traldi P., Fedele D. Importance of measuring
phys Acta 2006; 1757: 509-517.
products of non-enzymatic glycation of proteins. Clin Bio-
29. Reznick R.M., Shulman G.I. The role of AMP-activated
protein kinase in mitochondrial biogenesis. J Physiol 2006;
chem 2005; 38: 103-115.
574:33-39.
43. Sheu S.S., Nauduri D., Anders M.W. Targeting antioxidants
30. Gibson B.W. The human mitochondrial proteome: oxida-
to mitochondria: a new therapeutic direction. Biochim Bio-
tive stress, protein modifications and oxidative phosphory- phys Acta 2006; 1762 :256-265.
pag. 62
Nr. 6/martie 2009
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68